Spruce Biosciences
SPRB
35 hedge funds and large institutions have $24.7M invested in Spruce Biosciences in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 4 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 36 → 35 (-1)
13% less capital invested
Capital invested by funds: $28.5M → $24.7M (-$3.75M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
+$3.34M |
| 2 |
B
Bailard
Foster City,
California
|
+$39.4K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$21.9K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$84K |
| 2 |
Goldman Sachs
New York
|
-$74.6K |
| 3 |
Morgan Stanley
New York
|
-$69.9K |
| 4 |
E
Ergoteles
New York
|
-$35.2K |
| 5 |
VF
Virtu Financial
New York
|
-$27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SG
26
StoneX Group
New York
| $13.8K | -$3.49K | -25 | -16% |
|
27
UBS Group
Zurich,
Switzerland
| $10K | +$3.08K | +22 | +28% |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $10K | +$8.11K | +58 | +145% |
|
29
Bank of America
Charlotte,
North Carolina
| $2K | -$2.79K | -20 | -53% |
|
30
Federated Hermes
Pittsburgh,
Pennsylvania
| $2K | +$280 | +2 | +15% |
|
31
Wells Fargo
San Francisco,
California
| $1K | -$699 | -5 | -36% |
|
32
Fidelity Investments
Boston,
Massachusetts
| $1K | – | – | – |
|
|
CAL
33
Capital Advisors Ltd
Shaker Heights,
Ohio
| $1K | +$839 | +6 | +300% |
|
|
VF
34
Virtu Financial
New York
| – | -$27K | -210 | Closed |
|
35
Legal & General Group
London,
United Kingdom
| – | -$1K | -10 | Closed |
|
36
Citigroup
New York
| – | -$1K | -5 | Closed |
|
37
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$140 | -1 | -50% |
|
SPRB Hedge Fund Activity: Q3 2022 in Review
35 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q3 2022, worth a combined $24.7M — down 13% from $28.5M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SPRB and 3 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 6 added.
The largest buyer was Abingworth, opening a new position worth an estimated $3.34M. The largest seller was Millennium Management, cutting an estimated $84K.
- 35 institutional investors held Spruce Biosciences (SPRB) as of Q3 2022, down from 36 in Q2 2022.
- Funds reported $24.7M of Spruce Biosciences stock for Q3 2022, down 13% quarter-over-quarter.
- 3 funds opened new Spruce Biosciences positions in Q3 2022 and 4 closed out, a net change of -1 holder.
- The largest Spruce Biosciences buyer in Q3 2022 was Abingworth, an estimated $3.34M added.
- The largest Spruce Biosciences seller in Q3 2022 was Millennium Management, an estimated $84K sold.
Based on aggregated 13F filings for Q3 2022.